EZH2 and melanoma: This result indicated that combination therapy could achieve better anticancer efficacy only in melanoma cell lines with concurrent BRAF V600E mutation and EZH2 gain, and the effects of GSK126 treatment may involve inhibition of PI3K signaling pathway.